This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
CPRX gears up to report Q2 results as Firdapse sales rise, Agamree grows, and Fycompa faces a post-patent dip.
CPRXPositive Net Change ACADPositive Net Change DNLIPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?
by Ekta Bagri
EXEL rides on strong Cabometyx demand in RCC and NET, but Q2 sales miss and rising competition cloud the outlook.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change EXELNegative Net Change
biotechnology biotechs medical pharmaceuticals
KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook
by Zacks Equity Research
Krystal Biotech tops Q2 estimates with strong Vyjuvek sales, but shares fall 14% on weak Q3 revenue guidance.
BAYRYNegative Net Change CRMDPositive Net Change KRYSPositive Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
VTRS braces for Q2 results as branded drug growth in Europe and China offsets generic headwinds in North America.
PFENegative Net Change EXASNegative Net Change AMRXPositive Net Change VTRSNegative Net Change
biotechnology medical pharmaceuticals
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.
ZTSNegative Net Change ACADPositive Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO's second-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, Wegovy, Ozempic and Rybelsus.
NVONegative Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Central Garden (CENT)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
CENTNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
GILD Likely to Beat on Q2 Earnings: Buy, Sell or Hold the Stock?
by Zacks Equity Research
GILD eyes Q2 gains as demand for HIV drugs holds strong despite pricing pressures and cell therapy headwinds. We recommend investors to wait and watch for now.
GSKNegative Net Change MRKNegative Net Change GILDNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up
by Zacks Equity Research
Alnylam stock jumps 15% after a surprise Q2 profit, driven by soaring Amvuttra sales and raised 2025 revenue guidance.
REGNNegative Net Change ALNYNegative Net Change NVSNegative Net Change RHHBYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Zoetis Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
ZTS eyes an earnings beat as companion animal drugs like Simparica Trio and Apoquel are expected to drive Q2 revenue gains.
ZTSNegative Net Change EXASNegative Net Change BNTXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
by Zacks Equity Research
REGN stock up as Q2 EPS jumps 12% on strong Eylea HD and Dupixent profits, beating revenue and earnings estimates.
REGNNegative Net Change SNYNegative Net Change BAYRYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
After Golden Cross, Invesco (IVZ)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
IVZNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
by Ahan Chakraborty
BCRX gears up for Q2 results with Orladeyo growth in focus, but 2025 EPS forecasts dip as investors eye pipeline progress.
BCRXPositive Net Change IONSPositive Net Change NTLAPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
by Zacks Equity Research
TEVA tops Q2 earnings expectations as branded drugs shine, but revenues slip on weak generics and Japan exit.
JNJPositive Net Change TEVANegative Net Change ABBVPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View
by Zacks Equity Research
BMY's Q2 EPS and revenues beat estimates, powered by strong Growth portfolio sales and a lesser than expected decline in Legacy portfolio sales.
BMYNegative Net Change PFENegative Net Change EXELNegative Net Change BNTXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bausch Health Stock Falls on Q2 Earnings Miss, Revenues Beat
by Zacks Equity Research
BHC stock falls 6.3% as Q2 earnings miss estimates despite stronger sales and growth in key segments like Salix and Solta Medical.
CRMDPositive Net Change BHCNegative Net Change ARVNPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy Medpace (MEDP) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
MEDPNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
New Strong Sell Stocks for July 31st
by Zacks Equity Research
CELZ, GRFS and WHR have been added to the Zacks Rank #5 (Strong Sell) List on July 31, 2025.
WHRPositive Net Change GRFSPositive Net Change CELZPositive Net Change
biotechnology
Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
ALVO preps for Q2 results as investors eye early U.S. traction for Simlandi and Selarsdi, plus pipeline progress.
RDYPositive Net Change AMGNPositive Net Change TEVANegative Net Change ALVONegative Net Change
biotechnology biotechs medical pharmaceuticals
NVO Stock Crashes 22% After 2025 View Cut: More Downside Ahead?
by Ahan Chakraborty
Novo Nordisk stock plunges 22% after slashing 2025 sales and profit outlooks, citing weak GLP-1 drugs' uptake and rising competition.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
TEMENOS GROUP (TMSNY)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
TMSNYNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
TransAlta (TAC) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
TACPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Prime Medicine, Inc. (PRME) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
PRMEPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Regions Financial (RF) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
RFNo Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
by Ekta Bagri
CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech
ILMNPositive Net Change BEAMPositive Net Change EDITPositive Net Change NTLAPositive Net Change PRMEPositive Net Change CRSPPositive Net Change
biotechnology biotechs gene-editing gene-therapy genetics genomics medical pharmaceuticals